Biotech News & Trading Forum: Community User: Weedmaster

Na dann schauen wir doch mal wann sie die aktien auf den Markt werfen. Danach kann man immer noch zusteigen.

Das Atm ist schon beschlossen wie gepostet, sie können von Zeit zu Zeit wie sie wollen,bis der Wert von 40Mil erreicht ist.

Nehme an Rockwell wartet mit dem offering bis der Kurs wieder steigt. Mit dem zulassungstermin im März gehen die bestimmt von einem steigenden Kurs bis dahin aus. Dann wird ein offering bekannt gemacht ähnlich wie bei aquestive.

$TRIL macht da weiter wo sie am Freitag aufgehört hat 💪🏽

Danke 😊

Wow,schönes Ding Billi! 🙄👍 Von Schorsch am 0.8.12. A wie Akari Therapeutics: http://investor.akaritx.com/news-releases/news-release-details/akari-therapeutics-reports-third-quarter-2019-financial-results Eventuell Phase 3 Daten zu Coversin - CAPSTONE gegen Paroxysmal nocturnal hemoglobinuria (PNH) Phase 1/2 Part B Daten zu Coversin gegen Atopic keratoconjunctivitis Start Phase 3 Studie zu Coversin Hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA)

Itci 🥳🥳🚀

Hallo Jungs... Danke für die tolle Aufnahme bei euch und allem für die hervorragenden Aktien Informationen... die uns Anfänger den Einstieg sehr erleichtert ... hab mir einige aufgrund euerer Empfehlungen zugelegt! Danke für den fairen Austausch! 😘😘😘

FCINGO...definiere besser!? 😂

Aus dem letzten 10Q von Rockwell As of September 30, 2019, the Company had approximately $14.4 million of cash and cash equivalents, $14.6 million of investments available-for-sale, working capital of $28.2 million and an accumulated deficit of $299.2 million. Net cash used in operating activities for the nine months ended September 30, 2019 was approximately $21.9 million. The Company will require significant additional capital to sustain its operations and make the investments it needs to execute its longer-term business plan. The Company’s existing liquidity is not sufficient to fund its operations and anticipated capital expenditures within one year of the issuance of the accompanying condensed consolidated financial statements. The Company’s recurring operating losses, net operating cash flow deficits, and an accumulated deficit, raise substantial doubt about the Company’s ability to continue as a going concern for one year from the issuance of the accompanying condensed consolidated financial statements. The condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has not *** any adjustments to the accompanying condensed consolidated financial statements related to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. On June 20, 2019, the Company closed a public offering of 5,833,334 shares of common stock at a price of $3.00 per share. The aggregate proceeds from this public offering (net of the underwriters’ commissions and offering expenses) were approximately $16.1 million. On July 9, 2019, the underwriters of the public offering partially exercised their over-allotment option and purchased an additional 425,800 shares of common stock at a price of $3.00 per share, which closed on July 11, 2019. The aggregate proceeds from the exercise of the over-allotment option (net of the underwriters’ discount and offering expenses) were approximately $1.2 million. On March 22, 2019, the Company entered into a sales agreement with Cantor Fitzgerald & Co. (the “Agent”), pursuant to which the Company may offer and sell from time to time shares of the Company’s common stock through the Agent up to $40,000,000. As of September 30, 2019, approximately $37.7 million remains available for issuance under this facility. We are not required to sell any shares at any time during the term of the facility. Our ability to sell common stock under the facility may be limited by several factors including, among other things, the trading volume of our common stock and certain black-out periods that we may impose upon the facility, among other things. The Company will require additional capital to sustain its operations and make the investments it needs to execute upon its longer-term business plan, including the launch of Dialysate Triferic and I.V. Triferic. If the Company is unable to generate sufficient revenue from its existing long-term business plan, the Company will need to obtain additional equity Cash sieht nicht so gut aus und sie haben ein at the Market Offering über 40 Millionen Dollar am laufen was fast komplett noch genutzt werden kann.

Kal83 das es besser würd als bei Evofem 😉

Zu Rockwell hätte ich auch gerne ne Einschätzung von euch. Bitte - Danke. 😂

Moin Karmate! Danke für die Titel! Ich bin zeitlich leider sehr eingespannt und deswegen kommt von mir wohl nicht mehr viel. Wollte mir heute Abend noch ein paar Charts angucken. Rockwell gehört jedenfalls dazu.

Akari Therapeutics hat einen schon volatilen Chart. Hat jemand zu dieser Aktie mehr Informationen?

Finde es hier auch sehr Klasse und möchte mich für den guten Umgang recht herzlich bedanken und wünsche euch eine ruhige und besinnliche Weihnachtszeit ! fürs Jahr 2020 viele Gaiiiiiiloooos und 🚀

Ich habe so paar Aktien auf watchlist aufgenommen. Eure Meinung: Akari Therapeutics, SpectrumPharmaceuticals, Rockwell Medical, flexion Therapeutics, und impala platinum.